Compare JAZZ & SMTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JAZZ | SMTC |
|---|---|---|
| Founded | 2003 | 1960 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1B | 17.3B |
| IPO Year | 2007 | 2003 |
| Metric | JAZZ | SMTC |
|---|---|---|
| Price | $208.12 | $142.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 16 |
| Target Price | ★ $294.64 | $217.07 |
| AVG Volume (30 Days) | 715.2K | ★ 3.2M |
| Earning Date | 11-04-2026 | 11-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.65 |
| EPS | ★ 7.17 | 0.27 |
| Revenue | ★ $1,618,693,000.00 | $1,049,975,000.00 |
| Revenue This Year | $10.65 | $43.23 |
| Revenue Next Year | $5.76 | $35.87 |
| P/E Ratio | ★ $29.35 | $507.17 |
| Revenue Growth | N/A | ★ 15.47 |
| 52 Week Low | $128.80 | $60.28 |
| 52 Week High | $266.38 | $200.10 |
| Indicator | JAZZ | SMTC |
|---|---|---|
| Relative Strength Index (RSI) | 26.18 | 38.44 |
| Support Level | $194.77 | $117.45 |
| Resistance Level | $241.39 | $149.47 |
| Average True Range (ATR) | 6.94 | 10.67 |
| MACD | -1.78 | -7.00 |
| Stochastic Oscillator | 4.51 | 11.81 |
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Semtech Corp is a provider of high-performance semiconductors powering data center networking, Internet of Things ("IoT") connectivity, and cellular infrastructure solutions. The company designs, develops, manufactures, and markets a diverse portfolio of products for commercial applications, addressing the infrastructure, high-end consumer, and industrial end markets. The company operates in four reportable segments: Signal Integrity, Analog Mixed Signal and Wireless, IoT Systems, and Connected Services. The majority of the company's revenue is earned through the Analog Mixed Signal and Wireless segment. Geographically, the majority of the company's revenue is earned from the Asia Pacific region; the company also operates in North America and Europe.